Method of treating gastrointestinal motility disorders
First Claim
Patent Images
1. A method of treating a gastrointestinal hypermotility disorder in a subject in need thereof comprising administering to said subject an effective amount of a compound of formula I ##STR6## wherein Z1 is oxygen or sulphur;
- R is hydrogen;
halogen;
amino;
--NHCO--R2 ;
C3-7 -cycloalkyl;
C4-10 -(cycloalkylalkyl);
--Z2 --C3-7 -cycloalkyl optionally substituted with C1-6 -alkyl;
--Z2 --C4-10 -(cycloalkylalkyl);
--Z2 --C4-10 -(cycloalkenylalkyl);
--Z2 --C4-10 -(methylenecycloalkylakyl);
--NH--R2 ;
--NR2 R3 ;
--NH--OR2 ;
phenyl;
phenoxy;
benzoyl;
benzyloxycarbonyl;
tetrahydronaphthyl;
indenyl;
R2 ;
--Z2 R2 ;
--SOR2 ;
--SO2 R2 ;
--Z2 R2 --Z3 --R3 ;
--Z2 --R2 --Z3 --R3 --Z4 --R4 ;
--Z2 --R2 --CO--R3 ;
--Z2 --R2 --CO2 --R3 ;
--Z2 --R2 --O2 C--R3 ;
--Z2 --R2 --CONH--R3 ;
or --Z2 --R2 --NHCOR3 ;
wherein Z2, Z3 and Z4 independently are oxygen or sulphur, and R2, R3 and R4 independently are straight or branched C1-5 -alkyl, straight or branched C2-15 -alkenyl, straight or branched C2-15 -alkynyl, each of which is optionally substituted with halogen(s), --OH, --CN, --CF3, --SH, --COOH, --NH--R2, --NR2 R3, C1-6 -alkyl ester, one or two phenyl, phenoxy, benzoyl or benzyloxycarbonyl wherein each aromatic group is optionally substituted with one or two halogen, --CN, C1-4 -alkyl or C1-4 -alkoxy;
R5 and R6 may be present at any appropriate position and independently are hydrogen, straight or branched C1-5 -alkyl, straight or branched C2-5 -alkenyl, straight or branched C2-5 -alkynyl, straight or branched C1-10 -alkoxy, --OH, halogen, --NH2, carboxy, or straight or branched C1-5 -alkyl substituted with --OH; and
R1 is hydrogen, straight or branched C1-5 -alkyl, straight or branched C2-5 -alkenyl or straight or branched C2-5 -alkynyl;
ora pharmaceutically acceptable salt thereof.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to a method for treating a mammal suffering from gastrointestinal motility disorders comprising administering certain thiadiazole and oxadiazole compounds that are herein disclosed.
-
Citations
18 Claims
-
1. A method of treating a gastrointestinal hypermotility disorder in a subject in need thereof comprising administering to said subject an effective amount of a compound of formula I ##STR6## wherein Z1 is oxygen or sulphur;
-
R is hydrogen;
halogen;
amino;
--NHCO--R2 ;
C3-7 -cycloalkyl;
C4-10 -(cycloalkylalkyl);
--Z2 --C3-7 -cycloalkyl optionally substituted with C1-6 -alkyl;
--Z2 --C4-10 -(cycloalkylalkyl);
--Z2 --C4-10 -(cycloalkenylalkyl);
--Z2 --C4-10 -(methylenecycloalkylakyl);
--NH--R2 ;
--NR2 R3 ;
--NH--OR2 ;
phenyl;
phenoxy;
benzoyl;
benzyloxycarbonyl;
tetrahydronaphthyl;
indenyl;
R2 ;
--Z2 R2 ;
--SOR2 ;
--SO2 R2 ;
--Z2 R2 --Z3 --R3 ;
--Z2 --R2 --Z3 --R3 --Z4 --R4 ;
--Z2 --R2 --CO--R3 ;
--Z2 --R2 --CO2 --R3 ;
--Z2 --R2 --O2 C--R3 ;
--Z2 --R2 --CONH--R3 ;
or --Z2 --R2 --NHCOR3 ;
wherein Z2, Z3 and Z4 independently are oxygen or sulphur, and R2, R3 and R4 independently are straight or branched C1-5 -alkyl, straight or branched C2-15 -alkenyl, straight or branched C2-15 -alkynyl, each of which is optionally substituted with halogen(s), --OH, --CN, --CF3, --SH, --COOH, --NH--R2, --NR2 R3, C1-6 -alkyl ester, one or two phenyl, phenoxy, benzoyl or benzyloxycarbonyl wherein each aromatic group is optionally substituted with one or two halogen, --CN, C1-4 -alkyl or C1-4 -alkoxy;R5 and R6 may be present at any appropriate position and independently are hydrogen, straight or branched C1-5 -alkyl, straight or branched C2-5 -alkenyl, straight or branched C2-5 -alkynyl, straight or branched C1-10 -alkoxy, --OH, halogen, --NH2, carboxy, or straight or branched C1-5 -alkyl substituted with --OH; and R1 is hydrogen, straight or branched C1-5 -alkyl, straight or branched C2-5 -alkenyl or straight or branched C2-5 -alkynyl;
ora pharmaceutically acceptable salt thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
-
8. 2,5,6-Tetrahydro-1-methyl-3-(3-(3-hydroxy-1-propoxy)-1,2,5-thiadiazol-4-yl)pyridine;
-
1,2,5,6-Tetrahydro-1-methyl-3-(3-(2-phenyl-1-ethoxy)-1,2,5-thiadiazol-4-yl)pyridine; 1,2,5,6-Tetrahydro-1-methyl-3-(3-(3-hydroxy-1-hexyloxy)-1,2,5-thiadiazol-4-yl)pyridine; 1,2,5,6-Tetrahydro-1-methyl-3-(3-(3-phenyl-1-propoxy)-1,2,5-thiadiazol-4-yl)pyridine; 1,2,5,6-Tetrahydro-1-methyl-3-(3-(6-acetamido-1-hexyloxy)-1,2,5-thiadiazol-4-yl)pyridine; 1,2,5,6-Tetrahydro-1-methyl-3-(3-(2-acetamido-1-ethoxy)-1,2,5-thiadiazol-4-yl)pyridine; 1,2,5,6-Tetrahydro-1-methyl-3-(3-(2-propionamido-1-ethoxy)-1,2,5-thiadiazol-4-yl)pyridine; 1,2,5,6-Tetrahydro-1-methyl-3-(3-(2-benzylthio-1-ethoxy)-1,2,5-thiadiazol-4-yl)pyridine; 1,2,5,6-Tetrahydro-1-methyl-3-(3-(2-ureido-1-ethoxy)-1,2,5-thiadiazol-4-yl)pyridine; 1,2,5,6-Tetrahydro-1-methyl-3-(3-(2-ethylsulfinyl-1-ethoxy)-1,2,5-thiadiazol-4-yl)pyridine; 3-(3-(2,4-Dimethylphenylpropoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(3,4-Dimethylphenylpropoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(4-Fluorophenylpropoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(4-Chlorophenylpropoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(3-Methylphenylpropoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(4-Methylphenylpropoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-Phenylbutoxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(2-Methylphenylpropoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(2,5-Dimethylphenylpropoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-Methylthioethoxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-Dimethylaminoethoxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(3,4-Dichlorophenylpropoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-Dimethylaminopropoxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(4-Methylphenylpropoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(4-Cyclohexylbutoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(5-Hydroxyhexyloxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(5-Oxyhexyloxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(3-Cyclohexenylmethoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-Isobutylthioethoxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-Cyclopropylpropoxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(2-Methylcyclopropylmethoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-Cyclopentylpropyloxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(4,4,4-Trifluorobutoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(6,6,6-Trifluorohexyloxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(3-Cyclobutylpropoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-Isopropoxyethoxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(2,2,2-Trifluoroethoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(2-Chlorophenylpropoxy-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(3-Cyclohexylpropoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(2-Cyclohexylethoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine; 3-(3-(2,2,2-Trifluoroethoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydropyridine; 3-(3-(3-Carboxypropoxy)-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine;
ora pharmaceutically acceptable salt thereof.
-
Specification